2982-54-9

Usage

Uses

Used in Pharmaceutical Industry:
4-BENZYLOXY-3-AMINO-A-[-BENZYL-N-(1-METHYL-2P-METHOXY PHENYL ETHER) AMINO-METHYL BENZYL ALCOHOL is used as a pharmaceutical intermediate for its potential role in the development of new drugs, leveraging its complex structure and functional groups to create novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic chemistry, 4-BENZYLOXY-3-AMINO-A-[-BENZYL-N-(1-METHYL-2P-METHOXY PHENYL ETHER) AMINO-METHYL BENZYL ALCOHOL serves as a key compound in the synthesis of other organic molecules, potentially leading to the creation of new materials with specialized properties.

InChI:InChI=1/C15H17NO.ClH/c16-11-10-13-6-8-15(9-7-13)17-12-14-4-2-1-3-5-14;/h1-9H,10-12,16H2;1H

Upstream product

• 74447-33-9 1-(2'-azidoethyl)-4-(benzyloxy)benzene 
• 100-39-0 benzyl bromide 
• 838-96-0 2-[4-(benzyloxy)phenyl]acetonitrile 
• 14191-95-8 4-cyanomethylphenol 
• 51-67-2 tyrosamine 
• 74447-35-1 1-azido-2-(4-methylsulphonyloxyphenyl)ethane 
• 74447-34-0 1-azido-2-(4-hydroxyphenyl)ethane 
• 64318-28-1 N-t-butoxycarbonyl-tyramine 
• 182921-01-3 N-(tert-butoxycarbonyl)-2-[4-(benzyloxy)phenyl]ethylamine 

Downstream Products

• 1415684-17-1 (2S,3R,3aS,12bR)-1,2,3,3a,4,5,7,8-octahydro-11-benzyloxy-2-methyl-5-oxo-cyclopenta[2,3]pyrrolo[2,1-a]isoquinoline-3-carboxylic acid 
• 1415684-16-0 (2S,3R,3aS,12bR)-1,2,3,3a,4,5,7,8-octahydro-11-benzyloxy-2-methyl-3-nitromethyl-5-oxo-cyclopenta[2,3]pyrrolo[2,1-a]isoquinoline 
• 51179-05-6 2-(4-(benzyloxy)phenyl)ethanamine 
• 1410800-32-6 N-(4-(benzyloxy)phenethyl)-1H-pyrrolo[3,2-c]pyridine-2-carboxamide 
• 920525-70-8 3-((2-(4-benzyloxyphenyl)-ethylamino)-methyl)-7-methyl-chromen-2-one 
• 74447-32-8 O,O-dibenzoyltyrosol 
• 501-94-0 p-hydroxyphenethyl alcohol 
• 60-19-5 tyramine hydrochloride 

Relevant academic research and scientific papers

TETRAHYDROPROTOBERBERINE COMPOUND, PREPARATION METHOD THEREFOR AND USES THEREOF, AND PHARMACEUTICAL COMPOSITION

The present invention provides a tetrahydroprotoberberine compound represented by the formula (I), enantiomers, diastereomers, racemates and mixtures thereof, and pharmaceutically acceptable salts, crystalline hydrates and solvates thereof. The invention also provides a method for preparing the compound and the use thereof in the preparation of a medicament for preventing and/or treating central nervous system diseases.

CARBAMATE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Diverse alkaloid-like structures from a common building block

A wealth of unique enantiopure polycyclic alkaloid-like scaffolds can be prepared on a multigram scale in only a few steps from a common, commercially available intermediate. The attached nitromethyl group can then be used to construct highly diverse func

SYNTHESIS OF POLYCYCLIC ALKALOIDS

Disclosed embodiments concern polycyclic alkaloid compounds and methods for their use and synthesis. Particular embodiments concern polycyclic alkaloids having a fused, six-membered ring, while other embodiments concern polycyclic alkaloids having a fused

NOVEL CHROMEN-2-ONE BASED HYDROXAMIC ACID DERIVATIVES HAVING ANTI-INFLAMMATORY ACTIVITY, THE PREPARATION THEREOF AND A COMPOSITION CONTAINING THE SAME FOR TREATING INFLAMMATORY DISEASE

The present invention relates to novel chromen-2-one based hydroxamic acid derivatives having anti-inflammatory activity, the preparation thereof and a composition containing the same for treating inflammatory disease.

Trace amine-associated receptor agonists: Synthesis and evaluation of thyronamines and related analogues

We have previously shown that several thyronamines, decarboxylated and deiodinated metabolites of the thyroid hormone, potently activate an orphan G protein-coupled receptor in vitro (TAAR1) and induced hypothermia in vivo on a rapid time scale [Scanlan, T. S.; Suchland, K. L.; Hart, M. E.; Chiellini, G.; Huang, Y.; Kruzich, P. J.; Frascarelli, S.; Crossley, D. A.; Bunzow, J. R.; Ronca-Testoni, S.; Lin, E. T.; Hatton, D.; Zucchi, R.; Grandy, D. K. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat. Med. 2004, 10 (6), 638-642]. Herein, we report the synthesis of these thyronamines. Additionally, a large number of thyroamine derivatives were synthesized in an effort to understand the molecular basis of TAAR1 activation and hypothermia induction. Several derivatives were found to potently activate both rTAAR1 and mTAAR1 in vitro (compounds 77, 85, 91, and 92). When administered to mice at a 50 mg/kg dose, these derivatives all induced significant hypothermia within 60 min and exhibited a hypothermic induction profile analogous to 3-iodothyronamine (1, T1AM) except 91, which proved to be more efficacious. On the basis of this result, a dose-dependent profile for 91 was generated and an ED50 of 30 μmol/kg was calculated. Compound 91 proved to be more potent than T1AM for TAAR1 activation and exhibits increased potency and efficacy for hypothermia induction. These data further strengthen the pharmacological correlation linking TAAR1 activation by thyronamines and hypothermia induction in mice.